PE-22-28

PE 22-28 is a synthetic derivative of Spadin, an endogenous peptide that specifically blocks the TREK-1 potassium channel, a recently identified target for treating depression. PE 22-28 has been shown to induce neurogenesis after just four days, substantially faster than conventional antidepressant medications, and to stimulate synaptogenesis with fewer side effects than traditional pharmacological approaches.